Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Cellyan Biotechnology CoHKPD -13.55%18 EV-to-OCF is -23.77 as of Aug. 29, 2026. GuruFocus rates HKPD with a GF Score™ of 18/100. The stock has 3 warning signs investors should review. Among 119 Medical Distribution companies, Cellyan Biotechnology Co ranks better than 89.92% on this metric.
The historical rank and industry rank for Cellyan Biotechnology Co's EV-to-OCF or its related term are showing as below:
HKPD'
s EV-to-OCF Range Over the Past 10 Years
Min: -80.5 Med: 12.88 Max: 31.17
Current: -23.77
During the past 4 years, the highest EV-to-OCF of Cellyan Biotechnology Co was 31.17. The lowest was -80.50. And the median was 12.88.
HKPD's EV-to-OCF is ranked better than 89.92% of 119
companies
in the Medical Distribution industry
Industry Median: 8.14
vs HKPD: -23.77
EV-to-OCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Cellyan Biotechnology Co (NAS:HKPD) EV-to-OCF Explanation
EV-to-OCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Cellyan Biotechnology Co's PE Ratio (TTM) for today is calculated as:
Cellyan Biotechnology Co's share price for today is $0.3472.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Cellyan Biotechnology Co's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2026 was $-0.041.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Enterprise Value is used because it is a more complete measure in reflecting how much an investor pays when buying a company. Cash Flow from Operations is an important financial metric because it represents the cash generated from operating activities at a company's disposal. Companies with a low EV-to-OCF ratio, combined with a strong balance sheet are generally considered as undervalued.
Cellyan Biotechnology Co EV-to-OCF Related Terms
Cellyan Biotechnology Co EV-to-OCF Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Medical Distribution subindustry, Cellyan Biotechnology Co's EV-to-OCF, along with its competitors' market caps and EV-to-OCF data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Cellyan Biotechnology Co EV-to-OCF vs Medical Distribution Industry
For the Medical Distribution industry and Healthcare sector, Cellyan Biotechnology Co's EV-to-OCF distribution charts can be found below:
* The bar in red indicates where Cellyan Biotechnology Co's EV-to-OCF falls into.
Cellyan Biotechnology Co's current Enterprise Value is $17.88 Mil.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Cellyan Biotechnology Co's Cash Flow from Operations for the trailing twelve months (TTM) ended in Mar. 2026 was $-0.75 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Cellyan Biotechnology Co (HKPD) has a EV-to-OCF of -23.77 as of Aug. 29, 2026. According to the industry distribution chart, Cellyan Biotechnology Co ranks #12 out of 119 companies in the Medical Distribution industry, placing it in the top 10.1%.
Is Cellyan Biotechnology Co's EV-to-OCF too high?
Cellyan Biotechnology Co's current EV-to-OCF is -23.77. Based on the distribution chart, Cellyan Biotechnology Co ranks #12 out of 119 companies in the Medical Distribution industry, which is in the top quartile — a strong position relative to peers. Overall, Cellyan Biotechnology Co has a GF Score™ of 18/100, reflecting its overall financial health beyond just this single metric.
How does Cellyan Biotechnology Co's EV-to-OCF compare to MEDS and COSM?
According to the Medical Distribution industry distribution chart, Cellyan Biotechnology Co ranks #12 out of 119 companies for EV-to-OCF. This places Cellyan Biotechnology Co in the top 10% of its industry — outperforming the majority of peers. The industry median EV-to-OCF is 8.14. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-OCF for a Medical Distribution company?
The median EV-to-OCF among Medical Distribution companies is 8.14, based on 119 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-OCF significantly above this median, while those in the bottom quartile fall well below. However, EV-to-OCF should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-OCF mean?
A high EV-to-OCF can signal that a stock is expensive relative to its fundamentals. For the Medical Distribution industry, the median EV-to-OCF is 8.14 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Cellyan Biotechnology Co's current EV-to-OCF is -23.77. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Cellyan Biotechnology Co stock overvalued right now?
Cellyan Biotechnology Co (HKPD) has a current EV-to-OCF of -23.77. The current EV-to-OCF is -23.77. Cellyan Biotechnology Co's overall GF Score™ is 18/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-OCF calculated?
EV-to-OCF is calculated from a company's financial statements. For Cellyan Biotechnology Co (HKPD), the current EV-to-OCF is -23.77 as of Aug. 29, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Cellyan Biotechnology Co Ltd formerly, Hong Kong Pharma Digital Technology Holdings Ltd operates in two main categories: OTC pharmaceutical cross-border e-commerce supply chain services, conducted through its Hong Kong subsidiary, Joint Cross Border, which it refers to as the Supply Chain Services division, and OTC pharmaceutical cross-border procurement and distribution, conducted through its Hong Kong subsidiary, V-Alliance, which it referred to as the Procurement and Distribution division. Based in Hong Kong, Joint Cross Border has established itself as a provider of third-party supply chain services in Mainland China's OTC pharmaceutical cross-border e-commerce market.
18GF Score
Get the complete analysis for HKPD
EV-to-OCF is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
HKPD has been successfully added to your 
